GeneDx Holdings (WGS) Receivables - Other (2020 - 2026)

GeneDx Holdings (WGS) has reported Receivables - Other for 7 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other changed N/A year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (changed N/A YoY), while the FY2025 annual figure was $5.6 million, changed N/A from the prior year.
• Receivables - Other eased to $4.8 million in Q1 2026 per WGS's latest filing, from $5.6 million in the prior quarter.
• Across five years, Receivables - Other topped out at $23.6 million in Q3 2024 and bottomed at $25000.0 in Q4 2023.
• Historically, Receivables - Other has averaged $6.3 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Other soared 2677.78% — and 2023, when it plunged 98.33%.
• GeneDx Holdings' Receivables - Other stood at $1.5 million in 2022, then slumped by 98.33% to $25000.0 in 2023, then surged by 94192.0% to $23.6 million in 2024, then plunged by 76.41% to $5.6 million in 2025, then slipped by 14.57% to $4.8 million in 2026.
• Business Quant data shows WGS's Receivables - Other at $4.8 million in Q1 2026, $5.6 million in Q4 2025, and $23.6 million in Q3 2024.